Authors

• Min Qing (ORCID: https://orcid.org/0000-0001-9491-0360)
• Spyros Triantos
• Liming Peng (ORCID: https://orcid.org/0000-0001-9891-9581)
• Xiaodan Tang (ORCID: https://orcid.org/0000-0001-7493-623X)
• Wu‐Chou Su (ORCID: https://orcid.org/0000-0003-2953-4105)
• Joon Oh Park (ORCID: https://orcid.org/0000-0001-6502-2612)
• Yin‐Hsun Feng (ORCID: https://orcid.org/0000-0002-8660-0685)
• Do‐Youn Oh (ORCID: https://orcid.org/0000-0003-1663-9901)
• Hussein Sweiti
• Bhumsuk Keam (ORCID: https://orcid.org/0000-0001-8196-4247)
• Chong Zhang (ORCID: https://orcid.org/0000-0001-9609-8855)
• Lin Shen (ORCID: https://orcid.org/0000-0002-1205-049X)
• Xiufeng Liu (ORCID: https://orcid.org/0000-0003-3888-0333)
• Huimin Liao (ORCID: https://orcid.org/0009-0008-8463-6474)
• Jiaqi Qian (ORCID: https://orcid.org/0000-0002-4608-8293)
• Sang-We Kim

Institutions

• Ulsan College (KR)
• Peking University (CN)
• Asan Medical Center (KR)
• Samsung Medical Center (KR)
• Seoul National University Hospital (KR)
• University of Ulsan (KR)
• Peking University Cancer Hospital (CN)
• Chi Mei Medical Center (TW)
• Janssen (United States) (US)
• National Cheng Kung University Hospital (TW)
• Sungkyunkwan University (KR)

Publication Details

Journal

BMC Cancer

Published

2024-08-13

DOI

https://doi.org/10.1186/s12885-024-12584-0

Citations

13

Primary Topic

Cholangiocarcinoma and Gallbladder Cancer Studies

Type

article

Field-Weighted Citation Impact

7.45

Funders

• Astex Pharmaceuticals
• Janssen Research and Development